Aligos Therapeutics to Present Data from its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD’s The Liver Meeting® 2021

SOUTH SAN FRANCISCO, Calif., October 14, 2021 (GLOBE NEWSWIRE) – Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company focused on developing new therapies to address unmet medical needs in viral diseases and liver disease, today announced the upcoming poster presentations highlighting data from its clinical programs in chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH) at the 2021 Liver Meeting®, hosted by the American Association for the Study of Liver Diseases (AASLD), which will be held virtually November 12 – 15, 2021.

All displayed posters will be available on the Aligos website during scientific presentations and conferences after the conference concludes.

Chronic hepatitis B

Oligonucleotide polymers that are S antigen transport inhibitors (STOPPEDMT)

Title: Oligonucleotide polymers that are S antigen transport inhibitors, (STOPPEDMT) Sequestering cellular proteins to reduce the expression of hepatitis B virus S antigen and increase its proteasomal degradation
Publication number: 845
Session title: Hepatitis B: Therapeutic: New Agents
Presenter: C. Cheng Kao

Capsid Assembly Modulator (CAM)

Title: Safety, pharmacokinetics (PK) and antiviral activity of the capsid assembly modulator (CAM) ALG-000184 in subjects with chronic hepatitis B (CHB)
Publication number: 843
Session title: Hepatitis B: Therapeutic: New Agents
Presenter: Ed Gane

Antisense oligonucleotide (ASO)

Title: Best Antisense Oligonucleotides Against Hepatitis B Virus: Next Generation Bridged Nucleic Acid Chemistries Rise Dramatically In Vivo Efficacy and reduction of hepatotoxicity in mice
Publication number: 820
Session title: Hepatitis B: Therapeutic: New Agents
Presenter: Dinah misner

Title: ALG-020572, an antisense oligonucleotide conjugated to GalNAc, demonstrates In Vivo Efficacy and favorable preclinical profile for the treatment of chronic hepatitis B
Publication number: 819
Session title: Hepatitis B: Therapeutic: New Agents
Presenter: Kusum Gupta


Title: Incorporation of new siRNA chemistries dramatically improves potency and durability of HBV siRNAs in the AAV-HBV mouse model
Publication number: 831
Session title: Hepatitis B: Therapeutic: New Agents
Presenter: Jin hong


Title: Triple Hepatitis B Virus Drug Combination Demonstrates Synergistic Activity In vitro
Publication number: 852
Session title: Hepatitis B: Therapeutic: New Agents
Presenter: Hua Tan


Title: Preclinical pharmacokinetic profiling of ALG-055009, a potent and selective beta-agonist of thyroid hormone receptors for the treatment of non-alcoholic steatohepatitis, and prediction of its human pharmacokinetics
Publication number: 1932
Session title: NAFLD and NASH: therapeutic
Presenter: Kusum Gupta

Title: Development of a new seven-day dose efficacy model in mice to evaluate thyroid hormone receptor agonists for the treatment of NASH
Publication number: 1907
Session title: NAFLD and NASH: therapeutic
Presenter: Xuan Luong

About Aligos
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company that was founded in 2018 with a mission to become a global leader in the treatment of viral infections and liver disease. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as its expertise in liver disease to create targeted therapies for non-alcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience of its team in liver disease, particularly viral hepatitis, to rapidly advance its portfolio of potentially best-in-class molecules. their category.

Forward-looking statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts may be considered “forward-looking statements”. Forward-looking statements are generally, but not always, identified by the use of words such as “could”, “will”, “would”, “believe”, “intend”, “plan”, “anticipate”, “Estimate,” “expect” and other similar terms indicating future results. These forward-looking statements are subject to substantial risks and uncertainties which could cause our development programs, future results, performance or achievements to differ materially from those anticipated in forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties inherent in the drug development process, including the stage of clinical development of Aligos, the process of designing and conducting clinical trials, the processes of regulatory approval, the timing of regulatory filings, challenges associated with drug manufacturing, Aligos ‘ability to successfully establish, protect and defend its intellectual property, other issues that could affect the adequacy of Aligos’ capital resources to fund its operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on our business of the global COVID-19 pandemic. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as the risks associated with Aligos ‘business in general, see Aligos’ quarterly report on Form 10 -Q filed with the Securities and Exchange Commission on August 5, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Unless required by law, Aligos makes no commitment to update forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unforeseen events.

Media contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
[email protected]

Investor contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]

Previous Schumer plans to vote on election legislation next week, anticipating GOP blockade
Next Native asks London Transit for 'more sensitivity' after being denied service

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *